Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederesmo.org
ESMO News
Get the latest updates from ESMO News directly as they happen.
Follow now 73 followers
Latest posts
Last updated about 10 hours ago
FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
about 10 hours ago
Evidence for efficacy is based on the results from the CHECKMATE-8HW study
EMA Recommends to Extend the Indications for Tislelizumab
1 day ago
New indication concerns a combination with etoposide and platinum chemotherapy for the...
Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours
3 days ago
Findings from the analysis of TRACERx and MSK-IMPACT studies
ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025
3 days ago
ESMO Breast Cancer 2025 will take place between 14-17 May in Munich...
Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes
4 days ago
Findings from the CoPPO study
InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure
5 days ago
A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma
FDA Approves Durvalumab for Muscle Invasive Bladder Cancer
8 days ago
Evidence for efficacy is based on the results from the NIAGARA study
EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin
10 days ago
Trabectedin Accord is a generic of Yondelis, which has been authorised in...
A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI
10 days ago
Findings from the BARCODE1 study
Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer
11 days ago
Findings from the API-CAT study
Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas
12 days ago
Findings from the EREMISS study
FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC
15 days ago
Evidence for efficacy is based on the results from the PSMAfore study